Date | Time | Source | Headline | Symbol | Company |
12/06/2006 | 8:00AM | PR Newswire (US) | Lexapro(R) Demonstrated Significance on Prospectively Defined Efficacy Parameter and Was Better Tolerated Than Cymbalta(R) in Tr | NYSE:FRX | Forest Road Acquisition Corp |
12/01/2006 | 11:51AM | PR Newswire (US) | Seven Summits Research Releases Comments on GS, MCD, UAUA, FRX, and GPS | NYSE:FRX | Forest Road Acquisition Corp |
10/28/2006 | 12:08AM | PR Newswire (US) | Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2 | NYSE:FRX | Forest Road Acquisition Corp |
10/28/2006 | 12:08AM | PR Newswire (US) | Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2 | NYSE:FRX | Forest Road Acquisition Corp |
10/25/2006 | 9:52AM | PR Newswire (US) | Patient Recruitment for Desmoteplase Phase IIB/III Stroke Study DIAS-2 Placed on Hold | NYSE:FRX | Forest Road Acquisition Corp |
10/23/2006 | 8:00AM | PR Newswire (US) | U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem | NYSE:FRX | Forest Road Acquisition Corp |
10/17/2006 | 10:31AM | PR Newswire (US) | Seven Summits Research Releases Alerts on JNJ, EMC, FRX, UTX, and ODP | NYSE:FRX | Forest Road Acquisition Corp |
10/17/2006 | 8:57AM | PR Newswire (US) | Forest Laboratories Reports Earnings Per Share of $0.75 for Q2'07 | NYSE:FRX | Forest Road Acquisition Corp |
10/05/2006 | 5:51PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2007 Second Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
09/07/2006 | 9:00AM | PR Newswire (US) | Forest Laboratories Inc. Announces Appointment of Dr. Lawrence S. Olanoff as President and Chief Operating Officer | NYSE:FRX | Forest Road Acquisition Corp |
07/18/2006 | 10:31AM | PR Newswire (US) | Seven Summits Research Releases Alerts on HPQ, KO, UTX, FRX, and USB | NYSE:FRX | Forest Road Acquisition Corp |
07/18/2006 | 8:58AM | PR Newswire (US) | Forest Laboratories, Inc. Reports Fiscal First Quarter 2007 Results | NYSE:FRX | Forest Road Acquisition Corp |
07/13/2006 | 9:05PM | PR Newswire (US) | Forest Announces Federal Court Upholds Lexapro(R) Patent | NYSE:FRX | Forest Road Acquisition Corp |
07/11/2006 | 9:55AM | PR Newswire (US) | Forest Laboratories, Inc. and H. Lundbeck A/S File Lawsuit Against Caraco Pharmaceutical Laboratories, Ltd. for Patent Infringe | NYSE:FRX | Forest Road Acquisition Corp |
07/10/2006 | 3:14PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2007 First Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
05/18/2006 | 4:02PM | PR Newswire (US) | /C O R R E C T I O N -- Forest Laboratories, Inc./ | NYSE:FRX | Forest Road Acquisition Corp |
05/18/2006 | 3:26PM | PR Newswire (US) | Forest Laboratories Announces Nesli Basgoz, M.D. Named to Board of Directors | NYSE:FRX | Forest Road Acquisition Corp |
05/18/2006 | 3:25PM | PR Newswire (US) | Forest Laboratories, Inc. Announces New Share Repurchase Program | NYSE:FRX | Forest Road Acquisition Corp |
04/25/2006 | 12:18PM | PR Newswire (US) | Seven Summits Research Releases Comments on OXY, FRX, WHR, COH, and BNI | NYSE:FRX | Forest Road Acquisition Corp |
04/25/2006 | 9:07AM | PR Newswire (US) | Forest Laboratories, Inc. Reports Q4'06 Diluted Earnings Per Share of $0.28 Including $0.37 Per Share Charge for Licensing and | NYSE:FRX | Forest Road Acquisition Corp |
04/12/2006 | 5:05PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2006 Fourth Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
04/10/2006 | 9:00AM | PR Newswire (US) | Forest and Almirall Announce a Development and Marketing Collaboration Agreement on New Therapy for COPD | NYSE:FRX | Forest Road Acquisition Corp |
03/02/2006 | 8:30AM | PR Newswire (US) | Forest Laboratories Receives Patent Term Extension for Lexapro | NYSE:FRX | Forest Road Acquisition Corp |
02/23/2006 | 8:35AM | PR Newswire (US) | Replidyne and Forest Laboratories Announce FDA Acceptance for Review of New Drug Application for Oral Antibiotic Faropenem Medox | NYSE:FRX | Forest Road Acquisition Corp |
02/15/2006 | 6:07PM | PR Newswire (US) | /C O R R E C T I O N -- Forest Laboratories, Inc./ | NYSE:FRX | |
02/15/2006 | 4:05PM | PR Newswire (US) | Forest Laboratories Revises Research and Development Spending Projection to Account for Upfront Payments for Two Recent In-Licen | NYSE:FRX | Forest Road Acquisition Corp |
02/13/2006 | 8:20AM | PR Newswire (US) | Replidyne and Forest Laboratories Announce Faropenem Medoxomil Licensing Agreement | NYSE:FRX | Forest Road Acquisition Corp |
01/17/2006 | 8:09AM | PR Newswire (US) | Forest Laboratories, Inc. Reports Q3'06 Diluted Earnings Per Share of $0.57 Including $0.05 Per Share Licensing Payment | NYSE:FRX | Forest Road Acquisition Corp |
01/11/2006 | 6:15PM | PR Newswire (US) | Mylan Laboratories and Forest Laboratories Announce Nebivolol Licensing Agreement | NYSE:FRX | Forest Road Acquisition Corp |
01/05/2006 | 8:12AM | PR Newswire (US) | Forest Laboratories, Inc. and Cypress Bioscience, Inc. to Commence Third Milnacipran Phase III Trial | NYSE:FRX | Forest Road Acquisition Corp |